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MaOBJECTIVES The purpose of this study was to develop and validate a simple-to-use nomogram for prediction of
5-, 10-, and 15-year survival among asymptomatic adults.
BACKGROUND Simple-to-use prognostication tools that incorporate robust methods such as coronary artery calcium
scoring (CACS) for predicting near-, intermediate- and long-term mortality are warranted.
METHODS In a consecutive series of 9,715 persons (mean age: 53.4  10.5 years; 59.3% male) undergoing CACS, we
developed a nomogram using Cox proportional hazards regression modeling that included: age, sex, smoking,
hypertension, dyslipidemia, diabetes, family history of coronary artery disease, and CACS. We developed a prognostic
index (PI) summing the number of risk points corresponding to weighted covariates, which was used to conﬁgure the
nomogram. Validation of the nomogram was assessed by discrimination and calibration applied to a separate cohort of
7,824 adults who also underwent CACS.
RESULTS A total of 936 and 294 deaths occurred in the derivation and validation sets at a median follow-up of 14.6
years (interquartile range: 13.7 to 15.5 years) and 9.4 years (interquartile range: 6.8 to 11.5 years), respectively. The
developed model effectively predicted 5-, 10-, and 15-year probability of survival. The PI displayed high discrimination
in the derivation and validation sets (C-index 0.74 and 0.76, respectively), indicating suitable external performance of
our nomogram model. The predicted and actual estimates of survival in each dataset according to PI quartiles were
similar (though not identical), demonstrating improved model calibration.
CONCLUSIONS A simple-to-use nomogram effectively predicts 5-, 10- and 15-year survival for asymptomatic
adults undergoing screening for cardiac risk factors. This nomogram may be considered for use in clinical care.
(J Am Coll Cardiol Img 2018;11:450–8) © 2018 The Authors. Published by Elsevier on behalf of the
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AB BR E V I A T I O N S
AND ACRONYM S
CACS = coronary artery
calcium scoring
CAD = coronary artery disease
CI = conﬁdence interval
PI = prognostic index
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451E asy-to-use, well-validated tools for prognosti-cation of future events are important in clin-ical care, in particular for treatment
decisions in primary prevention (1,2). To date, how-
ever, little headway has been made in improving the
utility of prognostic tools by incorporating other
novel cardiac risk factors. For instance, coronary ar-
tery calcium scoring (CACS) is a robust method for
prediction of near- and intermediate-term adverse
clinical events, including mortality, nonfatal myocar-
dial infarction, and other major adverse cardiovascu-
lar events, with improved prognostic and risk
reclassiﬁcation value above and beyond clinical risk
factors alone (3–7). Moreover, McClelland et al. (8)
designed the MESA (Multi-Ethnic Study of Athero-
sclerosis) risk score, incorporating CACS, which can
be used to estimate 10-year risk for coronary heart
disease (CHD) and enables clinicians to determine
risk-based treatment strategies (8). However, the
risk of coronary atherosclerosis, as expressed by
CACS, goes beyond CHD alone. The MESA risk score
does not allow for the assessment of all-cause mortal-
ity as a surrogate for high-risk individuals by
increasing CACS. Although CHD risk assessment may
be a practical marker within clinical practice to deﬁne
preventive treatment strategies, tools for the identiﬁ-
cation of individuals with reduced survival are addi-
tionally warranted. In this study, we sought to
develop and validate a nomogram incorporating
CACS for prediction of near-, intermediate-, and
long-term mortality from any cause.SEE PAGE 459METHODS
STUDY POPULATION. The derivation set comprised
9,715 consecutive asymptomatic individuals referred
by physicians for coronary artery disease (CAD)
evaluation who underwent CACS at a single site
between January 1996 and December 1999 (Tennes-
see Heart and Vascular Institute, Hendersonville,
Tennessee). The validation set comprised 7,824
asymptomatic individuals who underwent CACS at
another single site between September 1998 and July
2011 (Cedars-Sinai Medical Center, Los Angeles, Cali-
fornia). The appropriate institutional review boards
at both sites approved the current study.
CLINICAL DATA COLLECTION. Traditional CAD risk
factors and veriﬁcation of asymptomatic states were
performed through direct interview by a physician or
allied health professional or by a structured medical
questionnaire. CAD risk factors queried included age,
sex, smoking, hypertension, diabetes, dyslipidemia,and family history of premature CAD. Sys-
temic arterial hypertension was deﬁned as a
documented history of high blood pressure or
treatment with antihypertensive medica-
tions. Diabetes mellitus was deﬁned by
diagnosis of diabetes made previously by a
physician and/or use of insulin or oral hypo-
glycemic agents. Dyslipidemia was deﬁned as
known but untreated dyslipidemia or current treat-
ment with lipid-lowering medications. A positive
smoking history was deﬁned as current smoking or
cessation of smoking within 3 months of testing.
Family history of early CAD was determined by asking
individuals whether any member of their immediate
family (i.e., parents or siblings) had a history of fatal
or nonfatal myocardial infarction and/or coronary
revascularization in a male relative age <55 years or a
female relative age <65 years. All data regarding the
aforementioned variables were available for analyses
in both cohorts.
CORONARY ARTERY CALCIUM IMAGE ACQUISITION
AND INTERPRETATION. All individuals underwent
Coronary artery calcium (CAC) testing using either a
C-100 or C-150 Ultrafast electron beam computed
tomography scanner (Imatron, South San Francisco,
California). Tomographic slice thickness was 3 mm,
with w40 axial images acquired from the level of the
carina to the level of the diaphragm. Coronary
calcium was deﬁned by >3 contiguous pixels with a
peak attenuation of $130 Hounsﬁeld units. CACS was
calculated according to the method of Agatston, and
was classiﬁed as 0, 1 to 100, 101 to 400, 401 to 1,000,
and >1,000. Estimated radiation dose was w1 mSv.
FOLLOW-UP PROCEDURES. Individuals belonging to
the derivation and validation sets were followed for
a median of 14.6 years (interquartile range [IQR]: 13.7 to
15.5 years) and 9.4 years (IQR: 6.8 to 11.5 years), respec-
tively, formortality from any cause. Deaths were veriﬁed
through query of the National Death Index.
STATISTICAL CONSIDERATIONS. Clinical character-
istics of the participants are summarized by mean 
SD for continuous measures and counts with
proportions for categorical features. Multivariable
time-to-event analysis was performed using Cox
proportional hazards regression models to develop a
nomogram using weighted estimators corresponding
to each covariate derived from ﬁtted Cox regression
coefﬁcients and estimates of variance (9,10). For Cox
proportional hazards regression analysis, CACS was
divided in the following 5 pre-deﬁned categories
according to the Agatston score; 0, 1 to 100, 101 to
400, 401 to 1,000, and >1,000, with CAC ¼ 0 as a
reference. A prognostic index (PI) was calculated by
TABLE 1 Clinical Features of the Derivation and Validation Sets
Derivation Set
(n ¼ 9,715)
Validation Set
(n ¼ 7,824)
Age, yrs 53.4  10.5 54.4  10.4
Male 5,765 (59.3) 5,359 (68.5)
Positive smoking history 3,817 (39.3) 638 (8.2)
Hypertension 4,220 (43.4) 3,004 (38.4)
Dyslipidemia 6,077 (62.6) 5,404 (69.1)
Diabetes 810 (8.3) 501 (6.4)
Family history of premature CAD 6,672 (68.7) 2,669 (34.1)
CAC score* 127 (119–135) 140 (131–149)
CAC score categories
0 4,864 (50.1) 3,888 (49.7)
1–100 2,759 (28.4) 2,160 (27.6)
101–400 1,255 (12.9) 1,015 (13.0)
401–1,000 559 (5.8) 485 (6.2)
>1,000 278 (2.9) 276 (3.5)
Values are mean  SD or n (%). *95% conﬁdence intervals are presented for
calcium scores.
CAC ¼ coronary artery calcium; CAD ¼ coronary artery disease.
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452summing the number of risk points corresponding to
each weighted covariate used to build the nomogram.
Individuals were subsequently classiﬁed for risk of
mortality by PI quartiles.
Validation of the nomogram was assessed by
discrimination and calibration. Harrell’s C-statistic
was calculated by 2,000-fold bootstrap resampling
iterations to an initial ﬁtted Cox model in the deri-
vation set. These development estimates were then
applied to yield a Harrell’s C-statistic in the validation
set. Model performance was further examined
through survival analysis using unadjusted Kaplan-
Meier curves by superimposing both datasets to
facilitate visual comparison of the discrimination. In
essence, a wider separation in the curves indicates
better discrimination.
Calibration of the nomogram was evaluated using a
reﬁtted Cox model in the derivation set to obtain the
linear prediction of the PI, then centering on its
mean. Next, we applied a second-degree fractional
polynomial regression to approximate the natural log
baseline cumulative hazard function as a smooth
function of time, and then predicted the baseline
survival function (Online Figure 1). We applied a Cox
regression post-estimation command to the PI and
corresponding baseline survival function across time
to obtain the predicted survival probabilities for each
PI quartile. We then generated a calibration plot
comparing the actual Kaplan Meier survival estimates
(with pointwise 95% conﬁdence intervals [CIs]) with
15-year predicted survival probabilities in both data-
sets. Further calibration of the PI obtained from the
nomogram was evaluated using the Hosmer-
Lemeshow goodness-of-ﬁt test according to 10 risk
groups. Statistical analyses for our nomogram con-
struction were performed in R software. All other
statistical calculations were computed using STATA
version 13.1 (StataCorp LP, College Station, Texas).
RESULTS
CLINICAL FEATURES AND CHARACTERISTICS. Of
the 9,715 individuals comprising the derivation set,
the mean age was 53.4  10.5 years, and 59.3% were
male (Table 1). One-half of the derivation set exhibi-
ted a CACS of 0, with decreasing prevalence of CACS
of 1 to 100 (28.5%), 101 to 400 (12.9%), 401 to 1,000
(5.8%), or >1,000 (2.9%). During a median follow-up
period of 14.6 years (IQR: 13.7 to 15.5 years), 936
deaths occurred. The 7,824 individuals in the vali-
dation set were slightly older, with a higher
frequency of men and with lower prevalence of
hypertension, diabetes, smoking, and family history
of premature CAD (Table 1). In the validation set,there was a higher prevalence of dyslipidemia
(Table 1). During a median follow-up period of 9.4
years (IQR: 6.8 to 11.5 years), 294 deaths occurred.
Each category of increasing CACS was similar
between the derivation and validation sets (Table 1).
NOMOGRAM PREDICTION OF ALL-CAUSE MORTALITY.
Multivariable hazard ratios were calculated for the
prognostic factors used to build the nomogram
(Table 2). In the derivation set, increasing age,
smoking, hypertension, diabetes, and increasing
CACS were associated with a greater risk of death
from all causes across 15 years of study follow-up,
with an observed attenuation of mortality risk for
individuals with dyslipidemia and family history of
premature CAD. These relationships were similar in
the validation set. The relationship between the
prognostic factors and risk of all-cause death did not
differ appreciably when re-examining the association
at 5- and 10-year study follow-up (Table 2).
Our PI was calculated based upon the weighted risk
of the individual CAD risk factors as follows: 11.3 þ
(1.12  age) þ (1  I[male sex]) þ (17  I[current
smoker]) þ (13  I[hypertension]) þ (11  I[1 
dyslipidemia]) þ (22  I[diabetes]) þ (8  I[1  family
history of premature CAD]) þ (13  CACS), where I[]
denotes the indicator function equal to 1 if the con-
dition in parenthesis is met, and 0 otherwise. Details
of the individual prognostic scores relative to each
risk factor are reported in Online Table 1. The distri-
butions of the calculated PI for the derivation and
validation sets are displayed in Online Figure 2. The
PI had a similar spread in both datasets. No outliers or
irregularities were observed.
TABLE 2 Multivariable Hazard Ratios for the Relationship Between Prognostic Risk Factors and 5-, 10-, and 15-Year All-Cause Mortality
5-Year Follow-Up 10-Year Follow-Up 15-Year Follow-Up
HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value
Derivation set
Age 1.04 1.03–1.05 <0.001 1.03 1.02–1.04 <0.001 1.04 1.03–1.04 <0.001
Male 1.15 0.90–1.45 0.26 1.03 0.88–1.20 0.72 1.02 0.90–1.17 0.72
Positive smoking history 1.92 1.54–2.41 <0.001 1.72 1.47–2.02 <0.001 1.71 1.51–1.95 <0.001
Hypertension 1.78 1.41–2.26 <0.001 1.59 1.35–1.88 <0.001 1.53 1.34–1.76 <0.001
Dyslipidemia 0.57 0.45–0.72 <0.001 0.69 0.59–0.81 <0.001 0.69 0.61–0.79 <0.001
Diabetes 1.69 1.27–2.24 <0.001 1.95 1.59–2.40 <0.001 2.01 1.69–2.38 <0.001
Family history of premature CAD 0.80 0.63–1.00 0.05 0.77 0.66–0.91 0.002 0.77 0.67–0.88 <0.001
CAC score
0 1.00 — — 1.00 — — 1.00 — —
1–100 2.29 1.65–3.16 <0.001 2.14 1.72–2.66 <0.001 1.98 1.66–2.36 <0.001
101–400 3.84 2.72–5.43 <0.001 3.38 2.68–4.25 <0.001 3.04 2.50–3.70 <0.001
401–1,000 4.07 2.70–6.11 <0.001 4.09 3.08–5.43 <0.001 4.02 3.20–5.05 <0.001
>1,000 6.36 4.15–9.73 <0.001 5.60 4.13–7.60 <0.001 5.13 3.97–6.63 <0.001
Validation set
Age 1.09 1.06–1.11 <0.001 1.09 1.07–1.11 <0.001 1.10 1.08–1.11 <0.001
Male 1.09 0.74–1.61 0.65 0.95 0.72–1.25 0.71 0.92 0.71–1.20 0.55
Positive smoking history 1.79 1.02–3.13 0.04 1.69 1.13–2.51 0.01 1.75 1.23–2.50 0.002
Hypertension 1.71 1.18–2.50 0.005 1.58 1.22–2.04 <0.001 1.46 1.14–1.86 0.002
Dyslipidemia 0.90 0.61–1.33 0.60 0.91 0.70–1.19 0.49 0.88 0.69–1.13 0.33
Diabetes 0.97 0.52–1.82 0.94 0.84 0.54–1.30 0.44 0.80 0.52–1.22 0.29
Family history of premature CAD 0.72 0.48–1.09 0.12 0.80 0.60–1.07 0.13 0.83 0.63–1.09 0.18
CAC score
0 1.00 — — 1.00 — — 1.00 — —
1–100 1.06 0.64–1.79 0.24 1.27 0.88–1.83 0.20 1.18 0.83–1.67 0.36
101–400 1.09 0.60–1.98 0.79 1.59 1.05–2.40 0.03 1.48 1.02–2.17 0.041
401–1,000 1.75 0.91–3.37 0.10 1.64 1.00–2.68 0.05 1.76 1.13–2.75 0.012
>1,000 1.34 0.61–2.96 0.47 2.52 1.55–4.11 <0.001 2.30 1.44–3.67 0.001
Hazard ratios using 2,000 bootstrap resampling are reported. Harrell’s C-index for the derivation set was 0.74. Applying the derivation set estimates to the validation set yielded a Harrell’s C-index of 0.76.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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453Table 3 reports the risk of death from all causes by
quartiles of the PI. Those comprising the very high-
risk group (PI >96 total risk points) represented 57%
and 58% of deaths in the derivation and validation
sets, respectively. Incident deaths for the highest
quartile in the derivation (17.28/1,000 person-years)
and validation sets (11.71/1,000 person-years) were
higher compared with lower quartiles. The highest
quartiles were associated with a >10-fold (95% CI:
7.99 to 13.63; p < 0.001) and 15-fold (95% CI: 9.57 to
25.93; p < 0.001) increased risk of death in the deri-
vation and validation sets, respectively, although the
pointwise 95% CIs for the latter dataset were some-
what wider given the lower number of events
observed. Based upon these ﬁndings, a nomogram
was conﬁgured (Figure 1).
VALIDATION OF NOMOGRAM. Harrell’s C-index for
the derivation set was 0.74. Applying the derivation
set estimates to the validation set yielded a similar
Harrell’s C-index of 0.76. A Kaplan-Meier survivalcurve for both datasets according to PI quartiles is
reported in Figure 2. Each set of the PI quartiles
appears well separated, indicating reasonable
discrimination in both datasets. Figure 3 displays
calibration plots comparing predicted survival prob-
abilities with actual Kaplan-Meier estimates in both
datasets according to PI quartiles. The patterns of
both plots were comparable (although not identical),
highlighting the similarity in the distribution of the PI
in both datasets, indicating suitable model calibra-
tion. Hosmer-Lemeshow goodness-of-ﬁt tests yielded
chi-squares of 7.59 (p ¼ 0.47) and 10.57 (p ¼ 0.23) for
the derivation and validation sets, respectively,
indicating no signiﬁcant deviation between observed
and predicted events in both datasets.
DISCUSSION
In a cohort of 9,715 asymptomatic individuals referred
for cardiac screening, we developed and validated a
simple-to-use nomogram-illustrated model for
TABLE 3 Risk of Death From All Causes According to Quartiles of the Prognostic Index
Prognostic Index Groups
Median Prognostic Index
Score (Range)*
No. of Persons
at Risk No. of Events
Event Rate/1,000 Person-Years
(95% CI)
Unadjusted HR
(95% CI) p Value
Derivation set
Quartile 1 52.4 (27.4–61.8) 2,424 60 1.70 (1.32–2.19) 1.00 —
Quartile 2 70.0 (62.1–77.3) 2,432 131 3.78 (3.19–4.49) 2.25 (1.66–3.05) <0.001
Quartile 3 85.6 (77.7–95.5) 2,429 207 6.14 (5.36–7.04) 3.69 (2.77–4.93) <0.001
Quartile 4 110.0 (96.0–167.7) 2,430 538 17.28 (15.88–18.80) 10.44 (7.99–13.63) <0.001
Validation set
Quartile 1 52.4 (27.6–62.0) 2,489 17 0.75 (0.47–1.21) 1.00 —
Quartile 2 69.7 (62.2–77.4) 1,947 49 2.82 (2.13–3.74) 3.76 (2.17–6.53) <0.001
Quartile 3 85.2 (77.6–95.6) 1,615 58 4.12 (3.18–5.33) 5.50 (3.20–9.43) <0.001
Quartile 4 112.1 (96.1–164.8) 1,773 170 11.71 (10.07–13.61) 15.75 (9.57–25.93) <0.001
*1st and 99th centile values are reported. Median prognostic index values were extracted from the overall score summed using the equation in text.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; IQR ¼ interquartile range.
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454predicting 5-, 10-, and 15-year survival. Our nomo-
gram model encompasses an extensive set of clinical
risk factors that are easy to obtain and routinely
collected by history, while also taking advantage ofFIGURE 1 Instructions for Using the Nomogram
Points
Age
Male Sex
Smoker
Hypertension
Dyslipidemia
Diabetes
Family history of
Premature CAD
CACS categories
Total Points
5-year survival prob.
10-year survival prob.
15-year survival prob.
10 20 30
10
0
1
0
1
0
1
0
11
0
0
1
2
1
0
20 30 4
0 20 40 60
0.99
0.99
0.99 0.95
0
Draw a line perpendicular from the corresponding axis of each risk factor
points for all risk factors then draw a line descending from the axis labe
determine 5-, 10-, and 15-year survival probabilities. For binary variable
2 ¼ 101 to 400, 3 ¼ 401 to 1,000, and 4 ¼ >1,000. CAD ¼ coronary a
probability.more novel cardiac screening modalities by incorpo-
rating CACS, a robust predictor of adverse health
outcomes (11–13). The nomogram of the present study
may be a valuable tool for clinical practice and can be40 50 60 70 80 90 100
4
3
0 50 60 70 80 90 100
0.95 0.9 0.8 0.7 0.6 0.50.4 0.3
0.95 0.9 0.8 0.7 0.60.50.40.30.2 0.1
0.9 0.8 0.7 0.6 0.50.4 0.3 0.2 0.10.05 0.01
80 100 120 140 160 180 200 220
until it reaches the top line labeled “POINTS.” Sum up the number of
led “TOTAL POINTS” until it intercepts each of the survival axes to
s, 0 ¼ no and 1 ¼ yes. For CACS categories, 0 ¼ none, 1 ¼ 1 to 100,
rtery disease; CACS ¼ coronary artery calcium score; prob. ¼
FIGURE 2 Comparison of the Discrimination Between Derivation and Validation Sets According to Quartiles of the Prognostic Score
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Solid lines indicate the derivation sets; dashed lines indicate the validation sets. Visual comparisons between the study sets were derived from
a Kaplan-Meier survival curve.
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455consulted to inform patients about their future risk
up to 15 years, incorporating the result of their CACS.
In addition, the results may be used as guidance for
preventive therapy, such as lipid-lowering therapy
for patients with a high risk of mortality. However,
comparative studies must be performed to assess the
effect of preventive therapeutic strategies based on
the current risk prediction mode.
Nomograms have frequently been used in cancer
prognosis, primarily for estimating the likelihood of
an event such as recurrence of early gastric cancer,
gynecologic cancer, or renal cancers (14–16). Lauer
et al. (17) developed and externally validated a
parsimonious nomogram-based model for predicting
all-cause mortality in adults with suspected CAD.
Furthermore, McClelland et al. (8) developed the
MESA risk score for the estimation of 10-year CHD risk
using traditional risk factors and CACS. Still, to date, a
nomogram that can predict 15-year all-cause mortal-
ity using CACS is unavailable. All-cause mortality can
be considered an appropriate outcome, because a
major proportion of deaths occur due to cardiac or
systemic atherosclerotic diseases, and this endpoint
is free from death misclassiﬁcation bias (18). Also, the
use of infrequently occurring cardiac-speciﬁc end-
points may introduce bias in relatively low-riskpopulations. Although focused treatment strategies
in clinical practice may be more easily deﬁned on the
basis of cardiac-speciﬁc risk assessment, the present
data unfortunately did not allow for this distinction.
Perhaps the most appealing aspect of our nomo-
gram model is its clinical applicability and ease of use
in a wide variety of health care systems. As an
example, a female age 65 years who is a nonsmoker; is
nonhypertensive, nondiabetic, and nondyslipidemic;
has a family history of premature CAD; and has a CAC
score of 90, will have a total risk score of 91 points,
which corresponds to a 5-, 10-, and 15-year probability
of survival of 95%, 92%, and 88% (Online Table 1,
Figure 1). In contrast, a male age 73 years who is a
current smoker; is hypertensive, nondiabetic, and
nondyslipidemic; does not have a family history of
premature CAD; and has a CAC score of 600, will have
a total risk score of 167 points, corresponding to a
5-, 10-, and 15-year probability of survival of 70%,
45%, and 25%, respectively (Figure 1). The current
ﬁndings support the prognostic potential of the
developed and validated nomogram, which is rela-
tively straightforward to understand and can be ob-
tained in little time using a simple intake form
(Online Table 1), or by accessing the online risk score
calculator.
FIGURE 3 Calibration Plot of a Cox Model for the Derivation and Validation Sets According to Quartiles of the Prognostic Score
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Smooth solid lines are predicted probabilities, and vertical capped lines are Kaplan-Meier (observed) estimates with 95% conﬁdence
intervals. Pink ¼ quartile 1; green ¼ quartile 2; blue ¼ quartile 3; gray ¼ quartile 4.
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456It is notable that dyslipidemia and a family history
of premature CAD were inversely related to the risk of
all-cause mortality, which may reﬂect the unmea-
sured confounding effect of lipid-lowering medica-
tions. Dyslipidemia was deﬁned as known but
untreated dyslipidemia or current treatment with
lipid-lowering medications. Hypothetically, the pro-
tective value of lipid-lowering therapy in patients
without established dyslipidemia could have excee-
ded the increased mortality risk of patients with true
dyslipidemia. The same may hold true for family
history of premature CAD. Indeed, others have pre-
viously reported a comparably low relative risk of
mortality in patients with hypercholesterolemia and a
family history of early CAD, potentially due to the
same confounders (4,19).
Nowadays, there is strong consensus between
researchers and physicians alike that a prognostic
model should not be permitted into clinical practice
unless it performs well and is “suitable for purpose”
(20). External validation is frequently used to estab-
lish whether a prognostic model performs well and if
it should enter clinical practice. We assessed theperformance of our survival model using 2 funda-
mental features of model validation: discrimination
and calibration (21). Using a high level of stringency,
our validation set comprising 7,824 persons differed
from those described in the derivation set with regard
to investigators, geographic location, and time
period. Furthermore, the prevalence of strongly
weighted prognostic risk factors, such as hyperten-
sion, smoking, and diabetes, was lower in the
validation cohort compared with the derivation
cohort. This resulted in a noticeable reduction of
all-cause mortality in the validation cohort. Despite
this, our model performed well, showing good
discrimination as reported by a C-index of 0.74 for the
derivation set and 0.76 for the validation set. Further
still, our model demonstrated reasonable calibration
based on Kaplan-Meier survival curves for both
datasets, albeit with some miscalibration. As noted
elsewhere (20,22), good discrimination is more crucial
to model validation than suitable calibration,
considering the latter can be recalibrated, whereas
the former cannot be altered (21). Still, the clinical
applicability of this prognostic screening model
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: A simple-to-use,
nomogram-illustrated model encompassing broader indicators of
cardiac risk, namely CACS, was developed and externally vali-
dated for predicting near-, intermediate-, and long-term death
from any cause. The present nomogram model should be
considered for its clinical applicability and ease of use across a
wide variety of health care settings.
TRANSLATIONAL OUTLOOK: The current nomogram model
was employed to predict risk of death from any cause. Forth-
coming studies are needed to examine whether this model may
prove useful in forecasting additional cause-speciﬁc events in
persons undergoing CACS.
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457depends on the circumstances and the tested
population. On the background of our model’s
favorable performance in our validation set, we
advocate the use of our PI for estimating near-,
intermediate-, and long-term survival in asymptom-
atic individuals. Undoubtedly, to ensure the robust-
ness of our model, the need for replication and
further validation of our ﬁndings in other
well-deﬁned populations, as well as for cause-speciﬁc
outcomes, is warranted.
STUDY LIMITATIONS. Although individuals were
considered free from CAD at baseline and representa-
tive of the general population; however, both cohorts
underwent cardiac screening procedures, which raises
concerns that these study individuals were referred by
physicians, and consequently may have inferred a
selection bias wherein the study sample may have
been at higher risk than a population-based cohort.
Despite this, common practice is that CAC scanning is
not performed without physician prescription, and
therefore, the current study sample likely reﬂects a
generalizable group of individuals. We were unable to
include other factors that could have inﬂuenced our
model such as ethnic background or medication use;
thus, caution should be used when extrapolating our
model to different populations. Nevertheless, we
developed the nomogram by evaluating individuals
from Nashville, Tennessee; validated the nomogram
in a distinct population from Los Angeles, California;
and observed robust prediction of the study ﬁndings.
These study results offer reassurance as to the gener-
alizability of the nomogram model. We developed our
nomogram using categorical variables to ensure
application as a simple-to-use clinical tool. This
parsimony may have led to less robust prognostic risk
prediction than if continuous variables were
employed (21). However, using categorical CACS
groups allowed for the integration of speciﬁc thresh-
olds associated with increased risk (23). Our nomo-
gram is amenable only to those who strictly possess
information regarding each risk factor included in the
model—whether prediction of survival based on our
model would improve depending on the inclusion of
other cardiac risk assessment tools, such as carotid
intimal medial thickness or C-reactive protein, is open
to question. Arguably, from a clinical standpoint, it
seems impractical to employ a different nomogram
each time a new risk factor becomes available. Further
still, the “revised” models themselves would require
external validation, and in any case, risk prediction
might not differ appreciably from the ﬁndings
reported using our model (21,24). Although the
availability of computed tomography scanners isubiquitous, rendering this procedure easy to perform
and highly accessible, it is important to note that there
is some radiation concern associated with CAC scan-
ning. Undoubtedly, though, the risk of future cardio-
vascular disease substantially outweighs the potential
risk of future fatal cancer conferred by radiation doses,
whichmimic that of screeningmammography. Despite
these ambiguities, our study has developed and
externally validated a robust nomogram for predicting
5-, 10-, and 15-year survival in asymptomatic adults
undergoing cardiac screening.
CONCLUSIONS
This nomogram consisting of 8 clinical characteristics
that are both straightforward to obtain and routinely
collected in cardiovascular risk assessment offers
clinicians a simple-to-use method for assessing mor-
tality risk in asymptomatic individuals being referred
for CAC scanning.
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